Doctors Note Logo

Published on: 8/18/2026

Why Aren't Bisphosphonates Improving My Bone Density?

Bisphosphonates may not improve bone density for several reasons, including incorrect dosing schedules, poor absorption when taken with food or drinks other than water, missed doses that reduce cumulative effect, or untreated vitamin D and calcium deficiencies that limit the drug's ability to build bone. Secondary conditions such as hyperparathyroidism, celiac disease, multiple myeloma, or ongoing steroid use can also blunt the response, and some people simply plateau after several years of treatment. It is also worth noting that stable bone density during bisphosphonate therapy is not automatically a failure, since preventing further loss is itself a meaningful outcome. There are several important factors to consider, and the details below can help you understand which ones apply to your situation.

If your bone density scans are not showing the improvement you expected, the reasons may be straightforward to identify and correct, but they are difficult to sort out without a structured review of your medications, nutrient levels, and other health conditions. A free, instant, online symptom check can help you organize what you are experiencing, flag possible contributing conditions, and give you clearer questions to bring to your next appointment.

Last reviewed for medical accuracy: 08/18/2026

answer background

Explanation

Why Aren’t Bisphosphonates Improving My Bone Density?

Bisphosphonates are among the most commonly prescribed medications for osteoporosis. They work by slowing down bone resorption, allowing your bones to maintain or increase density over time. Yet some patients find that their bone density scans (DEXA) don’t show the expected gains. If you’re facing this frustrating scenario, here are the most common reasons why bisphosphonates might not be improving your bone density—and what you can do next.


1. Issues with Medication Adherence and Administration

Even the most effective medication can fail if it isn’t taken correctly.

  • Missed doses
    Skipping weekly or monthly pills reduces overall exposure. Bisphosphonates have a long half-life in bone, but regular dosing is still crucial.
  • Improper timing
    These drugs should be taken first thing in the morning on an empty stomach, at least 30–60 minutes before food, drink (other than water), or other medications.
  • Positioning
    To minimize irritation of the esophagus and ensure absorption, remain upright (sitting or standing) for at least 30–60 minutes after taking your bisphosphonate.
  • Drug interactions
    Calcium, iron, antacids and certain supplements can bind to bisphosphonates in the stomach and prevent absorption. Always separate these by at least two hours.

2. Inadequate Calcium and Vitamin D Levels

Bisphosphonates need sufficient building blocks to strengthen bone.

  • Low calcium intake
    Adults generally need 1,000–1,200 mg of calcium daily. Dietary sources include dairy, leafy greens, fortified plant milks and supplements if needed.
  • Insufficient vitamin D
    Vitamin D helps your body absorb calcium. Aim for 800–1,000 IU daily, or more if blood tests show deficiency. Sunlight exposure and supplements both matter.
  • Monitoring
    Periodic blood tests for serum calcium and 25-hydroxyvitamin D ensure you’re in the optimal range.

3. Undiagnosed Secondary Causes of Bone Loss

Sometimes osteoporosis isn’t just “postmenopausal” or “age-related.” Underlying conditions can counteract bisphosphonate benefits.

  • Hyperparathyroidism
    Overactive parathyroid glands release excess parathyroid hormone (PTH), which increases bone resorption.
  • Thyroid disorders
    Both untreated hyperthyroidism and excessive thyroid hormone replacement can accelerate bone loss.
  • Gastrointestinal malabsorption
    Conditions like celiac disease, inflammatory bowel disease or chronic pancreatitis can impair nutrient absorption.
  • Chronic kidney disease
    Alters calcium/phosphorus balance and vitamin D activation.
  • Medications
    Long-term glucocorticoids, anticonvulsants and certain cancer therapies can undermine bone density.

If bisphosphonates aren’t helping, ask your doctor about a full blood work-up and review of your medical history to rule out these causes.


4. Plateau Effect and Duration of Therapy

Bone remodeling is a slow process, and results may plateau after initial gains.

  • Early response
    Most improvement occurs in the first 1–2 years of therapy. If you’ve been on a bisphosphonate for longer, a steady bone density may actually be a sign that bone loss has stopped.
  • Drug holidays
    After 3–5 years of oral therapy (or 6 years of IV therapy), your doctor may recommend a “drug holiday” to reduce potential long-term side effects like atypical femoral fractures. Regular monitoring continues during these breaks.
  • Switching therapies
    If bone density stagnates or you have new fractures, your provider may switch you to another class of drug (e.g., denosumab, teriparatide).

5. Measurement and Technique Variability

DEXA scans are the gold standard for measuring bone density, but they have limitations.

  • Different machines or technicians
    Calibration and operator technique can vary between facilities.
  • Changes in positioning
    Slight shifts in hip or spine angle can affect scores.
  • Natural variability
    A change of less than 3–5% may fall within the margin of error, rather than true bone loss.

Always compare scans done at the same center, with the same equipment and by experienced technicians whenever possible.


6. Lifestyle Factors

Your daily habits have a major impact on bone health.

  • Physical activity
    Weight-bearing exercise (walking, jogging, dancing) and strength training stimulate bone formation.
  • Smoking and alcohol
    Tobacco and excessive alcohol (more than two drinks per day) both impair bone remodeling.
  • Protein intake
    Adequate protein supports bone matrix; aim for about 0.8–1 g per kg of body weight, adjusted for age and kidney function.
  • Fall prevention
    Improving balance, home safety and vision reduces fracture risk, even if bone density isn’t rising.

Action Plan: Next Steps

  1. Review how you take your bisphosphonate
    Ensure proper timing, positioning and separation from other supplements.
  2. Check your calcium and vitamin D intake
    Get blood tests if you haven’t in the last 6–12 months.
  3. Screen for secondary causes
    Ask about lab work for PTH, thyroid function, kidney health and malabsorption.
  4. Reassess bone density measurements
    Use the same facility and equipment to minimize variability.
  5. Optimize lifestyle
    Add weight-bearing exercise, quit smoking, limit alcohol and maintain a balanced diet.
  6. Consider alternative therapies
    If density still isn’t improving, discuss other FDA-approved osteoporosis treatments with your doctor.

If you’re unsure about which factors might apply to you, try a free, online symptom check, using the doctor approved Ubie Symptom Checker to gather personalized insights before your next appointment.


When to Seek Immediate Medical Advice

While osteoporosis itself isn’t an emergency, certain symptoms warrant prompt evaluation:

  • Sudden, severe back pain
  • Signs of a recent fracture (swelling, inability to bear weight)
  • Any sign of jaw problems (pain, numbness) during treatment
  • Unexplained muscle weakness, cramps or heart rhythm changes

Discuss these—or any new, worrying symptom—with your healthcare provider right away. Always speak to a doctor about anything that could be life-threatening or serious.


Sticking with osteoporosis treatment can be challenging, especially if early scans don’t show the improvement you hoped for. By optimizing medication use, ruling out hidden causes, and making lifestyle adjustments, most people can stabilize or even improve their bone density over time. Keep your healthcare team in the loop, and use tools like the Ubie Symptom Checker to stay informed and proactive about your bone health.

(References)

  • * Hagino H. [Bisphosphonate]. Nihon Rinsho. 2015 Oct;73(10):1683-9. PMID: 26529930.

  • * Hu K, Adachi JD. Glucocorticoid induced osteoporosis. Expert Rev Endocrinol Metab. 2019 Jul;14(4):259-266. doi: 10.1080/17446651.2019.1617131. Epub 2019 May 16. PMID: 31094232.

  • * Watts NB, Chesnut CH 3rd, Genant HK, Harris ST, Jackson RD, Licata AA, Miller PD, Mysiw WJ, Richmond B, Valent D. History of etidronate. Bone. 2020 May;134:115222. doi: 10.1016/j.bone.2020.115222. Epub 2020 Jan 3. PMID: 31911206.

  • * Conradie M, de Villiers T. Premenopausal osteoporosis. Climacteric. 2022 Feb;25(1):73-80. doi: 10.1080/13697137.2021.1926974. Epub 2021 May 26. PMID: 34036859.

  • * Liu W, Lee B, Nagamani SCS, Nicol L, Rauch F, Rush ET, Sutton VR, Orwoll E. Approach to the Patient: Pharmacological Therapies for Fracture Risk Reduction in Adults With Osteogenesis Imperfecta. J Clin Endocrinol Metab. 2023 Jun 16;108(7):1787-1796. doi: 10.1210/clinem/dgad035. PMID: 36658750; PMCID: PMC10271227.

  • * Gopinath V. Osteoporosis. Med Clin North Am. 2023 Mar;107(2):213-225. doi: 10.1016/j.mcna.2022.10.013. Epub 2023 Jan 5. PMID: 36759092.

  • * Moore AE, Dulnoan D, Voong K, Ayis S, Mangelis A, Gorska R, Harrington DJ, Tang JCY, Fraser WD, Hampson G. The additive effect of vitamin K supplementation and bisphosphonate on fracture risk in post-menopausal osteoporosis: a randomised placebo controlled trial. Arch Osteoporos. 2023 Jun 20;18(1):83. doi: 10.1007/s11657-023-01288-w. Epub 2023 Jun 20. PMID: 37338608; PMCID: PMC10282078.

  • * Cosman F, Langdahl B, Leder BZ. Treatment Sequence for Osteoporosis. Endocr Pract. 2024 May;30(5):490-496. doi: 10.1016/j.eprac.2024.01.014. Epub 2024 Feb 2. PMID: 38311211.

  • * Li M, Ge Z, Zhang B, Sun L, Wang Z, Zou T, Chen Q. Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials. Arch Osteoporos. 2024 Sep 23;19(1):89. doi: 10.1007/s11657-024-01447-7. Epub 2024 Sep 23. PMID: 39312040; PMCID: PMC11420281.

  • * Lamy O, Everts-Graber J, Gonzalez Rodriguez E. Denosumab for osteoporosis treatment: when, how, for whom, and for how long. A pragmatical approach. Aging Clin Exp Res. 2025 Mar 8;37(1):70. doi: 10.1007/s40520-025-02991-z. Epub 2025 Mar 8. PMID: 40055268; PMCID: PMC11889064.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.